HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
Clinical trials for HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) explained in plain language.
Never miss a new study
Get alerted when new HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) trials appear
Sign up with your email to follow new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo shows promise in head and neck cancer trial
Disease control CompletedThis study tested whether adding an experimental drug (MK-1454) directly into tumors, along with the immunotherapy pembrolizumab, works better than pembrolizumab alone for adults with advanced head and neck cancer that has spread or cannot be removed. 18 participants were enrolle…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated May 26, 2026 02:48 UTC
-
New drug combo shows promise in early cancer trial
Disease control CompletedThis early-phase study tested a new drug (BGB-A445) alone and with another drug (tislelizumab) in 204 people with advanced solid tumors like lung, head and neck, and nasopharyngeal cancers. The main goals were to check safety and find the best dose. This is not a cure, but aims t…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
Phase: PHASE1 • Sponsor: BeiGene • Aim: Disease control
Last updated May 22, 2026 13:50 UTC
-
Shorter radiation may ease burden for older cancer patients
Symptom relief CompletedThis study tested a shorter radiation treatment schedule for people aged 70 and older with head and neck cancer. Standard treatment requires daily hospital visits for 6-7 weeks, which can cause severe side effects and lead to missed treatments. The goal was to see if a shorter co…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
Phase: NA • Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Symptom relief
Last updated May 26, 2026 03:11 UTC